Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ERA 2026

63rd European Renal Association (ERA) Congress

June 03 - 06, 2026

    1. All
    2. AAV
    3.  aHUS
    4. IgAN

    PDF

    Properdin inhibition as a novel therapeutic strategy in ANCA-associated vasculitis: a phase 2, randomized, double-blind clinical trial of tarperprumig

    PDF

    Ravulizumab in atypical haemolytic uraemic syndrome: post hoc analysis of dialysis and end-stage kidney disease in two phase 3 trials

    PDF

    Real-world effectiveness of ravulizumab in C5 inhibitor-naive patients with atypical haemolytic uraemic syndrome associated with an autoimmune trigger

    PDF

    Real-world effectiveness of ravulizumab in C5 inhibitor-naive patients with atypical haemolytic uraemic syndrome: association with time-to-treatment

    PDF

    Analysis of urinary soluble biomarkers in patients with IgA nephropathy: phase 2 SANCTUARY trial of ravulizumab

    PDF

    Impact of early proteinuria reduction on long-term eGFR outcomes among patients with IgA nephropathy in China: a retrospective cohort study

    PDF

    Insights from proteomic profiling of 24-hour urine in patients with IgA nephropathy in the phase 2 SANCTUARY trial of ravulizumab

    PDF

    Ravulizumab in IgA nephropathy: a prespecified interim analysis of a randomized phase 3 trial (I CAN)

    PDF

    Properdin inhibition as a novel therapeutic strategy in ANCA-associated vasculitis: a phase 2, randomized, double-blind clinical trial of tarperprumig

    PDF

    Ravulizumab in atypical haemolytic uraemic syndrome: post hoc analysis of dialysis and end-stage kidney disease in two phase 3 trials

    PDF

    Real-world effectiveness of ravulizumab in C5 inhibitor-naive patients with atypical haemolytic uraemic syndrome associated with an autoimmune trigger

    PDF

    Real-world effectiveness of ravulizumab in C5 inhibitor-naive patients with atypical haemolytic uraemic syndrome: association with time-to-treatment

    PDF

    Analysis of urinary soluble biomarkers in patients with IgA nephropathy: phase 2 SANCTUARY trial of ravulizumab

    PDF

    Impact of early proteinuria reduction on long-term eGFR outcomes among patients with IgA nephropathy in China: a retrospective cohort study

    PDF

    Insights from proteomic profiling of 24-hour urine in patients with IgA nephropathy in the phase 2 SANCTUARY trial of ravulizumab

    PDF

    Ravulizumab in IgA nephropathy: a prespecified interim analysis of a randomized phase 3 trial (I CAN)

    Disclaimer

    Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

    Connessiallasalute.it

    This site is intended for healthcare professionals practicing in the US.
    ©2026 AstraZeneca. All rights reserved.

    US-107328
    Last Updated 5/26

    Contact Us

    About Us

    AstraZeneca-US.com

    Grant Opportunities  

    Survey Feedback

    Your Privacy Choice

    Consumer Health Data
    Privacy Notice

    Privacy Notice | Legal Notice | Cookie Preferences

    Welcome to AstraZeneca Medical Information

    The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

     

    This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

     

    Are you a healthcare professional practicing in the United States?

    I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
    This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
    I am not a healthcare professional practicing in the United States